HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis

BACKGROUND: HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir....

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Tongjing, Xu, Hongtao, Cao, Lin, Ye, Maocong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5249087/
https://www.ncbi.nlm.nih.gov/pubmed/28107377
http://dx.doi.org/10.1371/journal.pone.0169444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5249087/
https://www.ncbi.nlm.nih.gov/pubmed/28107377
http://dx.doi.org/10.1371/journal.pone.0169444

Ejemplares similares